Ad5-survivin-transduced autologous dendritic cell vaccine

{
  "id": "MLC-T-ONC-009645",
  "term": "Ad5-survivin-transduced autologous dendritic cell vaccine",
  "field": "Oncology and biomedicine",
  "definition": "A cell-based cancer vaccine containing autologous dendritic cells (DCs) that are transduced with a replication-deficient adenovirus type 5 vector (Ad5) encoding a mutated form of the tumor-associated antigen (TAA) survivin, with potential immunostimulatory and antineoplastic activities. Upon administration, Ad5-survivin-transduced autologous DC vaccine may elicit an immune response against cancer cells expressing survivin by activating cytotoxic T cells (CTLs). This leads to an induction of cell death in survivin-positive tumor cells. Survivin, a member of the inhibitor of apoptosis (IAP) family of proteins, may be upregulated in certain tumor cell types and plays a key role in tumor cell growth and survival.",
  "synonyms": [
    "autologous dendritic cell adenovirus type 5-survivin vaccine",
    "Ad5-survivin-transduced autologous DC vaccine"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/ad5-survivin-transduced-autologous-dendritic-cell-vaccine/"
}